NCT07096258Recruiting
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
A Patient Registry Collecting the Clinical and Molecular Profiling Data of Patients With Locally Advanced and/or Metastatic, Unresectable, Stages IIIB/C or IV Non-small Cell Lung Cancer (NSCLC), Who Have Not Previously Been Treated for This Advanced Disease and Are Therefore Considered as Patients Receiving First-line Therapy.
Source: ClinicalTrials.gov · Last updated 31 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 24 Jul 2025
- Start date
- 1 Jun 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Hedera Dx SA
- Diseases
- Lung cancer
- NCT number
- NCT07096258
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Jun 2024 to the primary completion date, 31 Dec 2027
- 4 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.
Who the study is looking for
- Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
- Intention-to-initiate first-line tumour therapy for this advanced disease.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpitaux Universitaires Genève Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
| General Universitario Gregorio Marañon Coordinator of this site? Confirm its status | Madrid | Spain | Not yet recruiting |
| Université de Lorraine Coordinator of this site? Confirm its status | Nancy | France | Recruiting |
| University of Naples Federico II Coordinator of this site? Confirm its status | Naples | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.